A bifunctional fusion enzyme for one-step conversion of ABO blood group antigens on red blood cells, enzyme composition, application, and kit

By developing a bifunctional fusion enzyme for ABO blood group antigens on erythrocytes and a PBS/Tween-20 single buffer system, the problems of complex operation of multi-enzyme systems and incompatibility of buffer systems in existing technologies have been solved, realizing a simplified one-step conversion of type A, type B and type AB erythrocytes, and improving the stability and conversion efficiency of the enzyme.

CN123107968APending Publication Date: 2026-11-17SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611438998.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing enzymatic conversion systems for erythrocyte ABO antigens suffer from several problems, including complex operation of multi-enzyme systems, incompatibility of A/B antigen conversion module buffer systems, high structural burden of FP fusion enzymes, insufficient protein stability, and difficulty in achieving single-buffer one-step conversion of A, B, and AB type erythrocytes.

Method used

A bifunctional fusion enzyme was developed, comprising an A antigen conversion module, a B antigen conversion module, and a rigid linker peptide, using a PBS/Tween-20 single buffer system to achieve synchronous conversion of A and B antigens in the same buffer.

Benefits of technology

It enables one-step in vitro conversion of ABO antigens from type A, type B, and type AB erythrocytes, simplifying the operation process, improving enzyme stability and conversion efficiency, and reducing operational complexity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123107968A_ABST
    Figure CN123107968A_ABST
Patent Text Reader

Abstract

This disclosure presents a bifunctional fusion enzyme, enzyme composition, application, and kit for one-step ABO blood group antigen conversion on erythrocytes, belonging to the fields of bioengineering, enzyme engineering, transfusion medicine, and in vitro erythrocyte processing technology. The bifunctional fusion enzyme includes an A antigen conversion module, a B antigen conversion module, and a rigid linker peptide connecting the A antigen conversion module and the B antigen conversion module; wherein, the A antigen conversion module is FP1-FP2 lacking both the b-type CBM domain and the c-type CBM domain, or a functional variant with A antigen conversion activity, and the amino acid sequence of the A antigen conversion module is shown in SEQ ID NO:1; the B antigen conversion module is AmGH110A, or a functional variant with B antigen conversion activity, and the amino acid sequence of the B antigen conversion module is shown in SEQ ID NO:2; the rigid linker peptide contains (EAAAK). n This system can simultaneously support the activity of both the A antigen conversion module and the B antigen conversion module, enabling one-step in vitro conversion of type A, B, and AB erythrocytes into O-like erythrocytes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure belongs to the fields of bioengineering, enzyme engineering, transfusion medicine and in vitro processing of red blood cells, specifically relating to a bifunctional fusion enzyme for one-step conversion of red blood cell ABO blood group antigens, enzyme composition and its application, and a kit. Background Technology

[0002] The ABO blood group system is one of the most important blood group systems for clinical transfusion safety. Type A red blood cells express the A antigen, with α-N-acetylgalactosamine as the immunodominant terminal glycosyl group, while type B red blood cells express the B antigen, with α-galactose as the immunodominant terminal glycosyl group. Type O red blood cells lack the corresponding immunodominant A / B antigens. Therefore, type O red blood cells have significant application value in scenarios where crossmatching is limited or time is of the essence, such as emergency care, trauma treatment, disaster relief, and battlefield medical care.

[0003] Enzymatic digestion for removing A / B antigens from the surface of erythrocytes is a potential strategy for obtaining O-type erythrocytes. FpGalNAcDeAc and FpGalNase, derived from *Flavonifractor plautii* (FP1 and FP2), can synergistically remove A antigens; AmGH110A, derived from *Akkermansia muciniphila*, can remove B antigens. However, existing enzymatic conversion systems still have shortcomings. On the one hand, FP1 and FP2 contain multiple carbohydrate-binding modules (CBMs), leading to complex fusion protein structures and potentially affecting protein stability and engineered preparation. On the other hand, the A and B antigen conversion modules have different buffer system preferences; the FP1 / FP2-related modules are suitable for PBS conditions, while AmGH110A is more suitable for glycine buffer conditions. This means that simultaneous conversion of A / B dual antigens or AB-type erythrocytes usually requires sequential processing and buffer changes, increasing operational complexity.

[0004] Therefore, there is an urgent need to develop a compact, bifunctional fusion enzyme that possesses both A and B antigen conversion activities and can operate in a single buffer system to achieve one-step in vitro conversion of ABO antigens in A, B, and AB type erythrocytes. Summary of the Invention

[0005] This disclosure aims to at least address the problems existing in the prior art erythrocyte ABO antigen enzymatic conversion system, such as the complexity of multi-enzyme system operation, incompatibility of A / B antigen conversion module buffer systems, large structural burden of FP fusion enzyme, insufficient protein stability, and difficulty in achieving single-buffer one-step conversion of type A, type B, and type AB erythrocytes. It provides a bifunctional fusion enzyme, enzyme composition, application, and kit for one-step conversion of erythrocyte ABO blood group antigens.

[0006] In one aspect of this disclosure, a bifunctional fusion enzyme for one-step conversion of erythrocyte ABO blood group antigens is proposed, characterized in that the bifunctional fusion enzyme includes an A antigen conversion module, a B antigen conversion module, and a rigid linker peptide connecting the A antigen conversion module and the B antigen conversion module. The A antigen conversion module is FP1-FP2 that lacks the b-type CBM domain and the c-type CBM domain, or a functional variant with A antigen conversion activity. The amino acid sequence of the A antigen conversion module is shown in SEQ ID NO:1. The B antigen conversion module is AmGH110A, or a functional variant with B antigen conversion activity, and the amino acid sequence of the B antigen conversion module is shown in SEQ ID NO:2; The rigid linker peptide contains (EAAAK). n n is 1-5.

[0007] Optionally, the rigid linker peptide is (EAAAK)3, with the amino acid sequence shown in SEQ ID NO:3.

[0008] Optionally, the functional variant with A antigen switching activity has at least 80% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:1, and still has A antigen switching activity; The functional variant with B antigen switching activity has at least 80% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:2, and still has B antigen switching activity.

[0009] Optionally, the bifunctional fusion enzyme comprises, from the N-terminus to the C-terminus, the A antigen conversion module, the rigid linker peptide, and the B antigen conversion module; or, The bifunctional fusion enzyme consists of, from N-terminus to C-terminus, the B antigen conversion module, the rigid linker peptide, and the A antigen conversion module.

[0010] Optionally, the bifunctional fusion enzyme is Am-EAK-FP, which consists of AmGH110A, (EAAAK)3, and FP1-FP2 (without the b-type CBM domain and the c-type CBM domain) from the N-terminus to the C-terminus. The amino acid sequence of the bifunctional fusion enzyme is shown in SEQ ID NO:4.

[0011] The bifunctional fusion enzyme is FP-EAK-Am, which consists of FP1-FP2, (EAAAK)3, and AmGH110A, respectively, from the N-terminus to the C-terminus, with the b-type CBM domain and c-type CBM domain missing. The amino acid sequence of the bifunctional fusion enzyme is shown in SEQ ID NO:5.

[0012] Optionally, the bifunctional fusion enzyme further includes a purification tag located at the N-terminus or C-terminus, or may not include a purification tag; wherein, The purification tag is a 6×His tag.

[0013] In another aspect of this disclosure, an enzyme composition for in vitro conversion of erythrocyte ABO blood group antigens is provided, said enzyme composition comprising the bifunctional fusion enzyme described above and a single-buffered reaction system; wherein, The single-buffered reaction system contains PBS and a nonionic surfactant.

[0014] Optionally, the nonionic surfactant is Tween-20; wherein, The volume fraction of Tween-20 is 0.01%-0.1%.

[0015] In another aspect of this disclosure, an application of an enzyme composition is proposed, wherein the enzyme composition described above is used in the in vitro preparation of ABO antigen-reducing erythrocytes or O-like erythrocytes; wherein, The application method includes: The red blood cells to be treated are contacted with the enzyme composition described above, so that the bifunctional fusion enzyme acts on the A antigen and / or B antigen on the surface of the red blood cells.

[0016] In another aspect of this disclosure, a kit for in vitro conversion of erythrocyte ABO blood group antigens is provided, the kit comprising the bifunctional fusion enzyme described above, and PBS / Tween-20 reaction buffer or reagents for preparing PBS / Tween-20 reaction buffer.

[0017] Compared with the prior art, this disclosure has at least the following beneficial effects: First, this invention obtains FP1-FP2ΔCBM_b&c through structure-guided CBM truncation. This module has a higher soluble expression level and higher thermal stability than the parental FP1-FP2 fusion protein, while retaining A antigen conversion activity.

[0018] Secondly, this invention links FP1-FP2ΔCBM_b&c with AmGH110A via a rigid (EAAAK)3 linker peptide to obtain two bifunctional fusion enzymes, Am-EAK-FP and FP-EAK-Am, which can simultaneously retain A antigen conversion activity and B antigen conversion activity.

[0019] Third, this invention establishes a PBS buffer containing 0.05% (v / v) Tween-20 as a single-buffered reaction system. This system can simultaneously support the functioning of both the A antigen conversion module and the B antigen conversion module, avoiding buffer replacement between the A antigen and B antigen conversion steps.

[0020] Fourth, this invention can be used for one-step in vitro ABO antigen conversion of type A, type B and type AB red blood cells. The treated red blood cells show a decrease in A / B antigen detection signal, a decrease or disappearance of anti-A and / or anti-B agglutination reaction, while maintaining H antigen reactivity and normal red blood cell morphology. Attached Figure Description

[0021] Figure 1 This is a structural design and functional screening diagram of the FP1-FP2ΔCBM_b&c compact A antigen conversion module in Embodiment 1 of this disclosure; wherein, Figure 1 (A) shows the truncated FP1-FP2 and FP2-FP1 constructs designed based on CBM structural analysis; Figure 1 (B) shows the Tm values ​​and purified protein yields for each truncated construct; Figure 1 (C) shows the A-to-O conversion efficiency of each truncated construct for type A erythrocytes.

[0022] Figure 2 This diagram illustrates the construction, linker peptide screening, and thermostability testing of the bifunctional fusion enzyme in Example 2 of this disclosure; wherein, Figure 2 (A) shows four fusion enzyme constructs: FP-GS-Am, Am-GS-FP, FP-EAK-Am, and Am-EAK-FP; Figure 2 (B) shows the A-to-O conversion activity of four fusion enzymes in type A erythrocytes; Figure 2 (C) shows the B-to-O conversion activity of the four fusion enzymes in type B erythrocytes; Figure 2 (D) in the figure shows the Tm values ​​of FP1-FP2, FP1-FP2ΔCBM_b&c, Am-EAK-FP, and FP-EAK-Am.

[0023] Figure 3 This describes the antigenic conversion of type A and type B erythrocytes using FP1-FP2ΔCBM_b&c and AmGH110A in the PBS / Tween-20 single-buffered system of Example 3 of this disclosure; wherein, Figure 3 (A) shows the effect of PBS and glycine buffer on the activity of antigen conversion modules A and B; Figure 3 (B) shows the effect of PBS buffer containing 0.05% Tween-20 on the activity of antigen conversion modules A and B.

[0024] Figure 4 This is a diagram illustrating the one-step ABO antigen conversion and phenotypic verification of type A, B, and AB erythrocytes in the PBS / Tween-20 single-buffered system of Example 4 of this disclosure, using Am-EAK-FP and FP-EAK-Am. Figure 4 (A) shows the one-step conversion efficiency of Am-EAK-FP and FP-EAK-Am for type A, B and AB erythrocytes in PBS buffer containing 0.05% Tween-20; Figure 4 (B) shows the reaction of erythrocytes with anti-A and / or anti-B reagents before and after treatment, as detected by the gel microcolumn method. Detailed Implementation

[0025] To enable those skilled in the art to better understand the technical solutions of this disclosure, the disclosure will be further described in detail below with reference to the accompanying drawings and specific embodiments. It should be understood that the specific embodiments described herein are only used to explain this disclosure and represent a part of the embodiments of this disclosure, not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of this disclosure without creative effort are within the protection scope of this disclosure.

[0026] In one aspect, this disclosure provides a bifunctional fusion enzyme for one-step conversion of erythrocyte ABO blood group antigens, the bifunctional fusion enzyme comprising an A antigen conversion module, a B antigen conversion module, and a rigid linker peptide connecting the A antigen conversion module and the B antigen conversion module.

[0027] In some embodiments, the A antigen conversion module is FP1-FP2 (FP1-FP2ΔCBM_b&c) lacking the b-type CBM domain and the c-type CBM domain, or a functional variant with A antigen conversion activity. The amino acid sequence of the A antigen conversion module is shown in SEQ ID NO:1, which is a fusion module formed by FP1 and a truncated FP2 after deleting CBM_b and CBM_c from FP2.

[0028] As a further preferred option, FP1-FP2ΔCBM_b&c originates from Flavonifractor plautii of Fp GalNAcDeAc (FP1) and Fp GalNase (FP2), the amino acid sequence of which is shown in SEQ ID NO:1.

[0029] As a further preferred embodiment, the functional variant having A antigen switching activity has at least 80% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:1, for example, at least 80%, 85%, 90%, 95%, 98% or 99%, and the functional variant still has A antigen switching activity.

[0030] It should be noted that functional variants with A antigen switching activity refer to protein variants that retain the corresponding antigen switching activity despite having undergone one or more amino acid substitutions, deletions, insertions, or truncations based on the corresponding parental amino acid sequence. Specifically, A antigen switching activity refers to the ability to reduce the detection signal of A antigen on the surface of type A or AB erythrocytes.

[0031] In some embodiments, the B antigen conversion module is AmGH110A, or a functional variant having B antigen conversion activity, and the amino acid sequence of the B antigen conversion module is shown in SEQ ID NO:2.

[0032] As a further preferred option, AmGH110A is derived from Akkermansia muciniphila.

[0033] As a further preferred embodiment, the functional variant having B antigen switching activity has at least 80% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:2, for example, at least 80%, 85%, 90%, 95%, 98% or 99%, and the functional variant still has B antigen switching activity.

[0034] Similarly, functional variants with B antigen switching activity refer to protein variants that retain the corresponding antigen switching activity despite having undergone one or more amino acid substitutions, deletions, insertions, or truncations based on the corresponding parental amino acid sequence. B antigen switching activity refers to the ability to reduce the detection signal of B antigen on the surface of type B or AB erythrocytes.

[0035] In some embodiments, the rigid linker peptide comprises (EAAAK). n n is 1-5.

[0036] As a further preferred embodiment, the rigid linker peptide is (EAAAK)3, with the amino acid sequence shown in SEQ ID NO:3.

[0037] In other embodiments, the bifunctional fusion enzyme comprises, from the N-terminus to the C-terminus, the A antigen conversion module, the rigid linker peptide, and the B antigen conversion module.

[0038] As a further preferred embodiment, the bifunctional fusion enzyme is Am-EAK-FP, which consists of AmGH110A, (EAAAK)3, and FP1-FP2 (without the b-type CBM domain and c-type CBM domain) from the N-terminus to the C-terminus. The amino acid sequence of the bifunctional fusion enzyme is shown in SEQ ID NO:4.

[0039] It should be understood that the bifunctional fusion enzyme may also contain amino acid sequences that, except for optional purification tags, have at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:4, and still have A antigen conversion activity. These will not be listed here.

[0040] In other embodiments, the bifunctional fusion enzyme comprises, from the N-terminus to the C-terminus, the B antigen conversion module, the rigid linker peptide, and the A antigen conversion module.

[0041] As a further preferred embodiment, the bifunctional fusion enzyme is FP-EAK-Am, which consists of FP1-FP2, (EAAAK)3, and AmGH110A, respectively, lacking both the b-type CBM domain and the c-type CBM domain, from the N-terminus to the C-terminus. The amino acid sequence of the bifunctional fusion enzyme is shown in SEQ ID NO:5.

[0042] It should be understood that the bifunctional fusion enzyme may also contain amino acid sequences that, except for optional purification tags, have at least 80%, 85%, 90%, 95%, 98%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:5, and still have B antigen conversion activity. These will not be listed here.

[0043] In other embodiments, the bifunctional fusion enzyme may also include a purification tag located at the N-terminus or C-terminus, or may not include a purification tag.

[0044] As a further preferred option, the purification tag is a 6×His tag.

[0045] The bifunctional fusion enzyme system disclosed herein can simultaneously support the activity of both the A antigen conversion module and the B antigen conversion module, enabling one-step in vitro conversion of A, B, and AB type erythrocytes into O-like erythrocytes. The substrate can undergo relay catalysis between the two active sites, reducing the diffusion distance of substrate molecules in solution, resulting in more thorough removal of A / B antigens from the erythrocyte surface and higher blood type conversion efficiency.

[0046] In another aspect of this disclosure, an enzyme composition for in vitro conversion of erythrocyte ABO blood group antigens is provided, the enzyme composition comprising the bifunctional fusion enzyme and single-buffered reaction system described above.

[0047] In some embodiments, the single-buffered reaction system comprises PBS and a nonionic surfactant.

[0048] As a further preferred embodiment, the nonionic surfactant is Tween-20, wherein the volume fraction of Tween-20 is 0.01%-0.1%, preferably 0.025%-0.1%, and more preferably 0.05%. Here, the volume fraction refers to the volume fraction relative to the total volume of the single buffer reaction system.

[0049] The bifunctional fusion enzyme disclosed herein requires only a single buffer environment to maintain the catalytic activity of both enzyme domains simultaneously, without the need to match optimal buffer conditions for each of the two individual enzymes. It is compatible with the single-buffered reaction system composed of PBS and nonionic surfactants disclosed herein.

[0050] In another aspect of this disclosure, an application of a bifunctional fusion enzyme is proposed, in which the bifunctional fusion enzyme described above is applied to the in vitro preparation of ABO antigen-reduced erythrocytes or O-like erythrocytes.

[0051] In some embodiments, the specific application process includes: Red blood cells to be treated are contacted with the bifunctional fusion enzyme described above in a single buffer system containing PBS and Tween-20, so that the bifunctional fusion enzyme acts on the A antigen and / or B antigen on the surface of red blood cells, thereby reducing the detection signal of the A antigen and / or B antigen on the surface of red blood cells and obtaining O-like red blood cells. In some embodiments, the final concentration of the bifunctional fusion enzyme is 1-100 nM, preferably 5-50 nM, more preferably 15 nM; the reaction time is 1-60 min, preferably 5-30 min, more preferably 15 min.

[0052] In some embodiments, the red blood cells are type A, type B, or type AB red blood cells.

[0053] In another aspect of this disclosure, a kit for in vitro conversion of red blood cell ABO blood group antigens is provided, the kit comprising the bifunctional fusion enzyme described above, and PBS / Tween-20 reaction buffer or reagents for preparing PBS / Tween-20 reaction buffer.

[0054] Another aspect of this disclosure proposes an isolated nucleic acid molecule that encodes a bifunctional fusion enzyme.

[0055] In another aspect of this disclosure, an expression vector is proposed that contains the nucleic acid molecule described above.

[0056] It should be noted that the expression vector is a vector suitable for genetic engineering operations, and can be a prokaryotic expression vector or a eukaryotic expression vector; the vector type includes at least one of plasmid vectors, viral vectors, and shuttle vectors.

[0057] In another aspect of this disclosure, a host cell is proposed that comprises the nucleic acid molecule or the expression vector described above.

[0058] It should be noted that the host cell is an engineered host cell capable of recombinant expression of the bifunctional fusion enzyme, and can be a prokaryotic or eukaryotic host cell. For example, prokaryotic host cells include *E. coli* cells; eukaryotic host cells can be yeast cells, mammalian cells, etc. The host cell can be a competent cell, facilitating vector transformation or transfection; nucleic acid molecules can exist in free form within the host cell or be integrated into the host cell's genome.

[0059] The host cells disclosed herein can be used for recombinant fermentation to produce the bifunctional fusion enzyme described above: host cells are cultured under suitable culture conditions to induce the expression of the target protein, and then broken, separated and purified to obtain a biologically active bifunctional fusion enzyme, which can be further used for in vitro conversion of erythrocyte ABO blood group antigens.

[0060] The following will further illustrate the bifunctional fusion enzyme for one-step in vitro conversion of erythrocyte ABO blood group antigens and its application with specific examples: It should be noted that the raw materials and reagents used in the following examples are all commercially available products, or can be prepared by known methods. Experimental methods in the following examples that do not specify specific conditions are generally performed under conventional conditions as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 4th edition), or as recommended by the manufacturer.

[0061] Example 1: Construction and screening of the FP1-FP2ΔCBM_b&c compact A antigen conversion module To obtain a more compact and stable A antigen conversion module, this embodiment constructs various CBM-truncated FP fusion proteins based on the domain composition of FP1 and FP2, including FP1-FP2ΔCBM_c, FP1-FP2ΔCBM_b&c, FP1-FP2ΔCBMall, FP1ΔCBM_b-FP2ΔCBM_c, FP2-FP1ΔCBM_b, FP2-FP1ΔCBMall, and FP1ΔCBM_c-FP2ΔCBM_b. Figure 1 A). The constructs were expressed in Escherichia coli and purified by affinity chromatography and molecular sieve chromatography.

[0062] The purified protein yield, thermostability, and A antigen conversion activity of each construct were measured. Results showed that FP1-FP2ΔCBM_b&c had a higher purified protein yield and a higher Tm value compared to the parental FP1-FP2 fusion protein. Figure 1 B), while retaining A antigen conversion activity comparable to that of the parental protein ( Figure 1 C). Therefore, the A antigen conversion module FP1-FP2ΔCBM_b&c given in this embodiment 1 retains the CBM-a domain by deleting the CBM-b and CBM-c domains. Without reducing the catalytic activity of A antigen conversion or affecting the protein expression level, it significantly improves the thermal stability of the fusion protein, which is beneficial for the storage of enzyme preparations and in vitro erythrocyte conversion reactions. Therefore, FP1-FP2ΔCBM_b&c was selected as the A antigen conversion module in the subsequent bifunctional fusion enzyme.

[0063] Example 2: Construction of A / B antigen switching activity and thermostability assays for bifunctional fusion enzymes Am-EAK-FP and FP-EAK-Am Using FP1-FP2ΔCBM_b&c as the A antigen conversion module and AmGH110A as the B antigen conversion module, four bifunctional fusion proteins were constructed using flexible linker peptide (GGGGS)3 and rigid linker peptide (EAAAK)3, respectively. Figure 2 A): FP-GS-Am: FP1-FP2ΔCBM_b&c-(GGGGS)3-AmGH110A; Am-GS-FP: AmGH110A-(GGGGS)3-FP1-FP2ΔCBM_b&c; FP-EAK-Am: FP1-FP2ΔCBM_b&c-(EAAAK)3-AmGH110A; Am-EAK-FP: AmGH110A-(EAAAK)3-FP1-FP2ΔCBM_b&c.

[0064] Each fusion protein can have a 6×His tag attached to its C-terminus. The coding sequence can be synthesized, cloned into the pET-21a(+) expression vector, and transformed into... Escherichia coli The four fusion proteins were expressed in BL21(DE3). After expression and purification, their A antigen-conversion activities and B antigen-conversion activities were tested. The A antigen-conversion assay was performed in PBS at a concentration of 2 nM; the B antigen-conversion assay was performed in 200 mM glycine buffer at pH 6.8 at a concentration of 15 nM.

[0065] The results showed that FP-GS-Am, Am-EAK-FP, and FP-EAK-Am exhibited conversion efficiencies comparable to FP1-FP2ΔCBM_b&c in A antigen conversion, and Am-GS-FP also maintained high A antigen conversion activity. Figure 2 B). For B antigen conversion, the activities of Am-GS-FP, Am-EAK-FP, and FP-EAK-Am were comparable to those of AmGH110A, while the B antigen conversion activity of FP-GS-Am was significantly reduced. Figure 2 C).

[0066] Further thermostability analysis using DSF revealed that the thermomaturation values ​​(Tm) of both Am-EAK-FP and FP-EAK-Am were higher than those of the parental FP1-FP2 fusion protein, and also higher than those of FP1-FP2ΔCBM_b&c. Figure 2 D). The above results indicate that the rigid (EAAAK)3 linker peptide is beneficial for simultaneously maintaining the functions of both the A antigen switching module and the B antigen switching module, and Am-EAK-FP and FP-EAK-Am are preferred bifunctional fusion enzymes.

[0067] Example 3: Establishment of a PBS / Tween-20 single-buffer system This example demonstrates the activity of FP1-FP2ΔCBM_b&c-mediated A antigen transition and AmGH110A-mediated B antigen transition in different buffer systems. The test systems included PBS, 200 mM glycine buffer, and PBS buffer containing different concentrations of Tween-20.

[0068] The results showed that FP1-FP2ΔCBM_b&c maintained high A antigen conversion activity in PBS, but its activity decreased in glycine buffer; AmGH110A maintained high B antigen conversion activity in glycine buffer, but its activity decreased in PBS. Figure 3 A). Further screening with Tween-20 revealed that PBS buffer containing 0.05% (v / v) Tween-20 could simultaneously support the catalytic activity of FP1-FP2ΔCBM_b&c and AmGH110A. Figure 3 B), therefore, it was determined to be the preferred single-buffered reaction system.

[0069] Example 4: One-step conversion and phenotypic verification of type A, B and AB erythrocytes by Am-EAK-FP and FP-EAK-Am Type A, B, or AB erythrocytes were collected, washed, and resuspended in PBS buffer containing 0.05% (v / v) Tween-20. 15 nM of Am-EAK-FP or FP-EAK-Am was added to the erythrocyte suspension, and the reaction was carried out at room temperature for 15 min. After the reaction, the erythrocytes were washed, and the exposure of residual A antigen, residual B antigen, and H antigen was detected by flow cytometry.

[0070] The results showed that both Am-EAK-FP and FP-EAK-Am could effectively convert type A and type B erythrocytes, and simultaneously convert type AB erythrocytes. This indicates that Am-EAK-FP and FP-EAK-Am can achieve one-step ABO antigen conversion of type A, type B, and type AB erythrocytes in a PBS / Tween-20 single-buffered PCR system. Figure 4 A).

[0071] Type A, B, and AB erythrocytes treated with Am-EAK-FP or FP-EAK-Am were washed and prepared into erythrocyte suspensions. The reaction of erythrocytes with anti-A, anti-B, or anti-H reagents before and after treatment was detected using the gel microcolumn method. The results showed that the agglutination reaction of type A, B, and AB erythrocytes treated with Am-EAK-FP or FP-EAK-Am with anti-A and / or anti-B reagents was reduced or disappeared. Figure 4 B) indicates that the corresponding A / B antigenic determinants on the surface of red blood cells have been effectively removed.

[0072] It is understood that the above embodiments are merely exemplary embodiments used to illustrate the principles of this disclosure, and this disclosure is not limited thereto. For those skilled in the art, various modifications and improvements can be made without departing from the spirit and substance of this disclosure, and these modifications and improvements are also considered to be within the scope of protection of this disclosure.

Claims

1. A bifunctional fusion enzyme for one-step conversion of erythrocyte ABO blood group antigens, characterized in that, The bifunctional fusion enzyme includes an A antigen conversion module, a B antigen conversion module, and a rigid linker peptide connecting the A antigen conversion module and the B antigen conversion module. The A antigen conversion module is FP1-FP2 that lacks the b-type CBM domain and the c-type CBM domain, or a functional variant with A antigen conversion activity. The amino acid sequence of the A antigen conversion module is shown in SEQ ID NO:

1. The B antigen conversion module is AmGH110A, or a functional variant with B antigen conversion activity, and the amino acid sequence of the B antigen conversion module is shown in SEQ ID NO:2; The rigid linker peptide contains (EAAAK). n n is 1-5.

2. The bifunctional fusion enzyme according to claim 1, characterized in that, The rigid linker peptide is (EAAAK)3, and its amino acid sequence is shown in SEQ ID NO:

3.

3. The bifunctional fusion enzyme according to claim 1, characterized by The functional variant with A antigen switching activity has at least 80% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:1, and still has A antigen switching activity; The functional variant with B antigen switching activity has at least 80% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:2, and still has B antigen switching activity.

4. The bifunctional fusion enzyme according to any one of claims 1 to 3, wherein, The bifunctional fusion enzyme comprises, from N-terminus to C-terminus, the A antigen conversion module, the rigid linker peptide, and the B antigen conversion module; or... The bifunctional fusion enzyme consists of, from N-terminus to C-terminus, the B antigen conversion module, the rigid linker peptide, and the A antigen conversion module.

5. The bifunctional fusion enzyme according to claim 4, characterized in that, The bifunctional fusion enzyme is Am-EAK-FP, which consists of AmGH110A, (EAAAK)3, and FP1-FP2 (without the b-type CBM domain and c-type CBM domain) from the N-terminus to the C-terminus. The amino acid sequence of the bifunctional fusion enzyme is shown in SEQ ID NO:4; or, The bifunctional fusion enzyme is FP-EAK-Am, which consists of FP1-FP2, (EAAAK)3, and AmGH110A, respectively, from the N-terminus to the C-terminus, with the b-type CBM domain and c-type CBM domain missing. The amino acid sequence of the bifunctional fusion enzyme is shown in SEQ ID NO:

5.

6. The bifunctional fusion enzyme according to any one of claims 1 to 3, wherein, The bifunctional fusion enzyme also includes a purification tag located at the N-terminus or C-terminus; wherein, The purification tag is a 6×His tag.

7. An enzyme composition for in vitro conversion of red blood cell ABO blood group antigens, characterized in that, The enzyme composition comprises the bifunctional fusion enzyme according to any one of claims 1-6 and a single-buffered reaction system; wherein... The single-buffered reaction system contains PBS and a nonionic surfactant.

8. The enzyme composition of claim 7, wherein, The nonionic surfactant is Tween-20; wherein... The volume fraction of Tween-20 is 0.01%-0.1%.

9. The application of an enzyme composition, characterized in that, The enzyme composition according to claim 7 or 8 is used in the in vitro preparation of ABO antigen-reducing red blood cells or O-like red blood cells; wherein, The application method includes: The red blood cells to be treated are contacted with the enzyme composition of claim 7 or 8, so that the bifunctional fusion enzyme acts on the A antigen and / or B antigen on the surface of the red blood cells.

10. A kit for in vitro conversion of red blood cell ABO blood group antigens, characterized in that, The kit contains the bifunctional fusion enzyme as described in any one of claims 1-6, and PBS / Tween-20 reaction buffer or reagents for preparing PBS / Tween-20 reaction buffer.